Research to Further Improve Treatment Optimization in MS


An expert provides the necessary steps needed to bolster accuracy of prescribed disease-modifying therapies for MS and do away with outdated trial-and-error approaches.

Transcript below.

Le Hua, MD: I wouldn’t just limit this to siponimod (Mayzent; Novartis), but all of our therapies need to improve. We need to find a better way to figure out when that transition happens from purely a primarily inflammatory stage to just the leftover, underlying process. We know that starts from the very beginning, but we don’t have a good sense of what happens during that sweet spot of when patients transition.

The diagnostic accuracy of secondary progressive MS can take up to 2 to 3 years. As with everything, time is brain. The better we can accurately capture that transition point, the better we can target therapies. I do like the therapies that have a 2-compartment approach, having both peripheral inflammatory effects, as well as neurodegenerative effects because we know that neurodegeneration starts early on and continues as patients age. I do see in the future maybe having more neurodegenerative targets that might not necessarily have an anti-inflammatory component.

As the disease progresses, we should focus more on the actual processes that underlie neurodegeneration, with either reparative strategies, myelination strategies, or neuroprotective strategies.

Related Videos
Jessica Ailani, MD
Frederic Schaper, MD, PhD
Jaime Imitol, MD
Jason M. Davies, MD, PhD
Carolyn Bernstein, MD
Prashanth Rajarajan, MD, PhD
Mandy Alhajj, DO, James Dolbow, DO & Neel Fotedar, MD
Riley Bove, MD
© 2024 MJH Life Sciences

All rights reserved.